Ethics of genetic and biomarker test disclosures in neurodegenerative disease prevention trials

Neurology

Volumn 84, Issue 14, 2015, Pages 1488-1494

  Kim, Scott Y H ^a   Karlawish, Jason ^b   Berkman, Benjamin E ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER;

ALZHEIMER DISEASE; ARTICLE; CLINICAL RESEARCH; DEGENERATIVE DISEASE; ETHICS; GENETIC SCREENING; INFORMED CONSENT; PATIENT SELECTION; PREVENTION STUDY; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; SCIENTIFIC VALIDITY; SOCIAL PSYCHOLOGY; VALIDITY; CLINICAL TRIAL (TOPIC); GENETICS; HUMAN; INTERPERSONAL COMMUNICATION; STANDARDS;

ALZHEIMER DISEASE; BIOMARKERS; CLINICAL TRIALS AS TOPIC; HUMANS; INFORMED CONSENT; PATIENT SELECTION; TRUTH DISCLOSURE;

EID: 84926631311     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000001451     Document Type: Article

References (44)

1. Farrer LA, Brin MF, Elsas L, et al. Statement on use of apolipoprotein-e testing for Alzheimer disease. JAMA 1995;274:1627-1629
2. Johnson KA, Minoshima S, Bohnen NI, et al. Appropriate use criteria for amyloid PET: a report of the amyloid imaging task force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association. J Nucl Med 2013;54:476-490
3. Goldman JS, Hahn SE, Catania JW, et al. Genetic counseling and testing for Alzheimer disease: joint practice guidelines of the American College of Medical Genetics and the National Society of Genetic Counselors. Genet Med 2011;13:597-605
4. Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011;7:280-292
5. Reiman EM, Langbaum JB, Tariot PN. Alzheimer's prevention initiative: a proposal to evaluate presymptomatic treatments as quickly as possible. Biomark Med 2010;4:3-14
6. Sperling RA, Rentz DM, Johnson KA, et al. The A4 study: stopping AD before symptoms begin?. Sci Transl Med 2014;6:228fs213
7. Rosas HD, Doros G, Gevorkian S, et al. PRECREST: a phase II prevention and biomarker trial of creatine in atrisk Huntington disease. Neurology 2014;82:850-857
8. Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. (DIAN-TU). Available at: https://www.clinicaltrials.gov/ct2/show/NCT01760005?term5DIAN1TU&rank51. Accessed December 9, 2014
9. Biomarker Qualification for Risk of Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease (AD) and Safety and Efficacy Evaluation of Pioglitazone in Delaying Its Onset. Available at: http://www.clinicaltrials. gov/ct2/show/NCT01931566?spons5Zinfandel&rank51. Accessed December 9, 2014
10. Reiman EM, Langbaum JB, Fleisher AS, et al. Alzheimer's Prevention Initiative: a plan to accelerate the evaluation of presymptomatic treatments. J Alzheimers Dis 2011;26 (suppl 3):321-329
11. Meiser B, Dunn S. Psychological impact of genetic testing for Huntington's disease: an update of the literature. J Neurol Neurosurg Psychiatry 2000;69:574-578
12. Klitzman R, Thorne D, Williamson J, Chung W, Marder K. Disclosures of Huntington disease risk within families: patterns of decision-making and implications. Am J Med Genet A 2007;143A:1835-1849
13. Hamilton RJ, Bowers BJ, Williams JK. Disclosing genetic test results to family members. J Nurs Scholar 2005;37: 18-24
14. Klitzman R. Views of discrimination among individuals confronting genetic disease. J Genet Couns 2010;19:68-83
15. Bombard Y, Penziner E, Suchowersky O, et al. Engagement with genetic discrimination: concerns and experiences in the context of Huntington disease. Eur J Hum Genet 2008;16:279-289
16. Apse KA, Biesecker BB, Giardiello FM, Fuller BP, Bernhardt BA. Perceptions of genetic discrimination among at-risk relatives of colorectal cancer patients. Genet Med 2004;6:510-516
17. Hsiung R. Ethical concerns and pitfalls in neurogenetic testing. In: Illes J, Sahakian BJ, eds. The Oxford Handbook of Neuroethics. New York: Oxford University Press; 2011:529-551
18. A Study of Crenezumab Versus Placebo in Preclinical PSEN1 E280A Mutation Carriers to Evaluate Efficacy and Safety in the Treatment of Autosomal-Dominant Alzheimer Disease, Including a Placebo-Treated Noncarrier Cohort. Available at: https://www.clinicaltrials.gov/ct2/show/NCT01998841?term5colombia1alzheimer& rank52. Accessed December 9, 2014
19. Burke W, Antommaria AH, Bennett R, et al. Recommendations for returning genomic incidental findings?. We need to talk! Genet Med 2013;15:854-859
20. Jarvik GP, Amendola LM, Berg JS, et al. Return of genomic results to research participants: the floor, the ceiling, and the choices in between. Am J Hum Genet 2014; 94:818-826
21. Parkinsons Progression Markers Initiative (PPMI). Available at: https://www.michaeljfox.org/page.html?. parkinsons-progression-markers-initiative-about. Accessed December 9, 2014
22. Brookmeyer R, Johnson E, Ziegler-Graham K, Arrighi HM. Forecasting the global burden of Alzheimer's disease. Alzheimers Dement 2007;3:186-191
23. Friedrich MJ. Researchers test strategies to prevent Alzheimer disease. JAMA 2014;311:1596-1598
24. Emanuel EJ, Wendler D, Grady C. What makes clinical research ethical?. JAMA 2000;283:2701-2711
25. Hooper M, Grill JD, Rodriguez-Agudelo Y, et al. The impact of the availability of prevention studies on the desire to undergo predictive testing in persons at risk for autosomal dominant Alzheimer's disease. Contemp Clin Trials 2013;36:256-262
26. Dahodwala N, Connolly J, Farmer J, Stern MB, Jennings D, Siderowf A. Interest in predictive testing for Parkinson's disease: impact of neuroprotective therapy. Parkinsonism Relat Disord 2007;13:495-499
27. Steinbart EJ, Smith CO, Poorkaj P, Bird TD. Impact of DNA testing for early-onset familial Alzheimer disease and frontotemporal dementia. Arch Neurol 2001;58:1828-1831
28. Molinuevo JL, Pintor L, Peri JM, et al. Emotional reactions to predictive testing in Alzheimer's disease and other inherited dementias. Am J Alzheimers Dis Other Demen 2005;20:233-238
29. Cassidy MR, Roberts JS, Bird TD, et al. Comparing testspecific distress of susceptibility versus deterministic genetic testing for Alzheimer's disease. Alzheimers Dement 2008;4:406-413
30. Rahman B, Meiser B, Sachdev P, et al. To know or not to know: an update of the literature on the psychological and behavioral impact of genetic testing for Alzheimer disease risk. Genet Test Mol Biomark 2012;16:935-942
31. Green RC, Roberts JS, Cupples LA, et al. Disclosure of APOE genotype for risk of Alzheimer's disease. N Engl J Med 2009;361:245-254
32. Crozier S, Robertson N, Dale M. The psychological impact of predictive genetic testing for Huntington's disease: a systematic review of the literature. J Genet Couns 2015;24:29-39
33. Paulsen JS, Nance M, Kim JI, et al. A review of quality of life after predictive testing for and earlier identification of neurodegenerative diseases. Prog Neurobiol 2013;110:2-28
34. Sanderson S, Wardle J. Associations between anticipated reactions to genetic test results and interest in genetic testing: will self-selection reduce the potential for harm?. Genet Test 2008;12:59-66
35. Kolata G. How do you live knowing you might have an Alzheimer's gene?. New York Times 2012
36. Timman R, Roos R, Maat-Kievit A, Tibben A. Adverse effects of predictive testing for Huntington disease underestimated: long-term effects 7-10 years after the test. Health Psychol 2004;23:189-197
37. Halpern J, Arnold RM. Affective forecasting: an unrecognized challenge in making serious health decisions. J Gen Intern Med 2008;23:1708-1712
38. Sevdalis N, Harvey N. Predicting preferences: a neglected aspect of shared decision-making. Health Expect 2006;9: 245-251
39. Peters SA, Laham SM, Pachter N, Winship IM. The future in clinical genetics: affective forecasting biases in patient and clinician decision making. Clin Genet 2014; 85:312-317
40. Dillard AJ, Fagerlin A, Dal Cin S, Zikmund-Fisher BJ, Ubel PA. Narratives that address affective forecasting errors reduce perceived barriers to colorectal cancer screening. Soc Sci Med 2010;71:45-52
41. Lineweaver TT, Bondi MW, Galasko D, Salmon DP. Effect of knowledge of APOE genotype on subjective and objective memory performance in healthy older adults. Am J Psychiatry 2014;171:201-208
42. The Belmont Report: Ethical Principles and Guidelines for the Protection of Human Subjects of Research. Washington, DC: US Government Printing Office; 1978
43. Goldman J. New approaches to genetic counseling and testing for Alzheimer's disease and frontotemporal degeneration. Curr Neurol Neurosci Rep 2012;12:502-510
44. Beecher HK. Ethics and clinical research. New Eng J Med 1966;274:1354-1360